|
| 产品描述 |
| Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. |
| 化学结构 |
 |
| 化学名称 |
| (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
| SMILES Code |
| O=C(NC1=NC=CC=C1)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]5N(C(C#CC)=O)CCC5)=N3)C=C2 |
| 基本信息 |
产品编号:XM001
产品名称:Acalabrutinib (ACP-196)
别名:ACP-196; ACP196; ACP 196; Acalabrutinib
CAS#:1420477-60-6
分子式:C26H23N7O2
精确分子量:465.19132
分子量:465.52
纯度:>98%
|
| 物化性质 |
外观: 白色固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温环境下运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限:3 年-20℃ 固体储存
2 年 -80℃溶于储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
